World COPD Day | Imaging Assessment in COPD Clinical Research

Source: EClinCloud. Author: EClinCloud.
November 13-15
November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life.
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1].

We have previously covered COPD scales; we welcome you to click and read:
How much do you know about daily diagnostic assessment for Chronic Obstructive Pulmonary Disease (COPD)? A must-read!
From diagnosis to treatment, these are the most commonly used COPD scales in clinical trials!
Today, we focus on imaging assessment in COPD clinical research.
With the development of quantitative lung CT analysis technology, CT has been gradually applied to the evaluation of emphysema severity, lung density, and airway structure. Through independent image review, unified evaluation standards, and quality control, IRC provides more objective and reliable imaging assessment support for clinical research.
COPD has different pathological manifestations, among which emphysema is one of the important structural changes, mainly characterized by the destruction of alveolar walls and abnormal enlargement of airspaces.
Pulmonary function tests mainly reflect the degree of airflow limitation, while chest CT can intuitively visualize changes in lung structure and further evaluate emphysema and airway lesions through quantitative analysis. In COPD clinical research, CT imaging mainly focuses on the following aspects:
Emphysema severity
By observing low-density areas of lung tissue to determine the extent and severity of lung parenchymal destruction.
Airway structural changes
Observing characteristics such as airway wall thickness, airway lumen, and airway remodeling to assist in the study of airway lesions.
Air trapping in the lungs
Using imaging such as expiratory CT to observe restricted airflow during expiration and evaluate imaging manifestations related to small airway dysfunction.
COPD imaging assessment has distinct disease characteristics, which impose specific requirements on image acquisition, quantitative analysis, and independent assessment.
Focus on overall and regional lung structural changes
Emphysema may involve multiple lung lobes, and the severity of lesions in different regions can vary. Therefore, imaging assessment not only needs to focus on the overall emphysema burden but also needs to identify structural changes in different lobes and regions, combining lung segmentation and quantitative analysis to form a more comprehensive evaluation result.
Higher requirements for CT scan standardization
CT measurement results are easily influenced by factors such as scan parameters, the degree of patient inspiration, and image reconstruction methods. For example, inconsistent inspiration levels across different visits may lead to deviations in lung density measurements.
Therefore, it is necessary to standardize scanning equipment, scan parameters, respiratory cooperation, and image processing workflows. The 2025 Fleischner Society position paper also emphasizes that standardized scanning protocols and quality control are essential for the quantitative evaluation of emphysema using CT[2].
Prioritizing longitudinal consistency across different visit timepoints
Some COPD clinical trials require CT scans at multiple timepoints to observe changes in lung density and the extent of emphysema. Therefore, in addition to ensuring the accuracy of individual image evaluations, it is necessary to unify scanning conditions, image processing, and quantitative analysis methods across different visits to ensure the comparability of longitudinal evaluation results.
Not all COPD clinical trials require independent imaging evaluation. Its value is more pronounced when imaging metrics are included as key efficacy endpoints, participant enrollment criteria, or when treatment effects need to be objectively evaluated through imaging.
Drug trials targeting emphysema progression
If a study aims to observe whether a treatment can slow the destruction of lung parenchyma, it may be necessary to continuously monitor changes in emphysema through quantitative CT lung density analysis.
Bronchoscopic interventional therapy and lung volume reduction device trials
For example, lung volume reduction treatments such as endobronchial valves and endobronchial coils typically require the use of CT imaging to evaluate the patient's emphysema distribution, the degree of lobar destruction, and the target treatment area. Furthermore, some studies also require evaluation of fissure integrity, lobar structure, and other imaging features relevant to treatment suitability.
IRC application stages:
Enrollment screening:HRCT evaluation of emphysema distribution, distribution and proportion of low-attenuation areas (LAA), degree of target lobe destruction, fissure integrity, etc., with blinded review by an independent reading team when necessary.
Efficacy endpoint evaluation:Depending on the study objectives, imaging changes between different timepoints are compared through quantitative CT analysis of metrics such as lung density, emphysema burden, lobar volume, airway structure, and air trapping.
Imaging safety review:Independent imaging review of abnormalities, such as pneumonia and pneumothorax, indicated in follow-up imaging provides imaging support for the investigator's safety assessments. Specific responsibilities are subject to the study protocol.
In summary, COPD imaging evaluation entails several requirements for IRC services:
First, possess expertise in thoracic imaging. Be familiar with emphysema, airway lesions, and related thoracic imaging features, and understand the clinical significance of different imaging metrics.
Second, establish standardized imaging quality control processes. Establish normalized requirements ranging from CT scanning protocols and patient respiratory cooperation to image reconstruction and quantitative analysis.
Third, ensure consistency in longitudinal evaluations. Standardize imaging evaluation criteria and analysis methods across different visit timepoints to reduce measurement bias.
Fourth, balance quantitative imaging analysis with expert reading. Combine quantitative analysis of lung structure with professional imaging assessment to improve the comprehensiveness and reliability of the evaluation.
Leveraging professional medical expert resources, the IRC system, and integrated services, the EClinCloud IRC solution provides independent and standardized imaging evaluation support for clinical research.
Regarding expert resources, medical and imaging experts in relevant fields can be organized to participate in evaluations, combined with different disease areas and study endpoints, to leverage the synergistic advantages of professional reading experience and clinical medical knowledge.
In terms of project implementation, EClinCloud establishes standardized processes centered around imaging acquisition guidance, imaging quality control, standardized reading, independent review, and results management, supporting the unified management and evaluation of multi-center imaging data, and reducing evaluation discrepancies between different centers and readers.
EClinCloud will continue to explore the deep integration of imaging evaluation technology and clinical research needs, providing high-quality imaging evaluation support for more innovative drug clinical research.
1. COPD Group, Chinese Thoracic Society. Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2013 Revision), Chinese Journal of Frontiers in Medicine 2014, Vol. 6, Issue 2
2. San José Estépar R, Barr RG, Fain SB, et al. The Use of Computed Tomography Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner Society[J]. American Journal of Respiratory and Critical Care Medicine, 2025, 211(5): 709–728. DOI: 10.1164/rccm.202410-2012SO.
EClinCloud is a leading AI company in the clinical research industry, dedicated to building an AI-driven, integrated clinical intelligence cloud platform and endpoint assessment technology. It provides global pharmaceutical companies and research institutions with technology products such as eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as services including scale management, linguistic validation, rater training, and data quality analysis. EClinCloud constructs efficient and precise digital solutions, and leverages AI predictive models and intelligent data platforms to dynamically assess and support the improvement of clinical trial success rates, helping to shorten drug/device development cycles and benefit patients.



